These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32376370)

  • 1. Lipid-mimicking peptide decorates erythrocyte membrane for active delivery to engrafted MDA-MB-231 breast tumour.
    Fan X; Xu H; Zhao F; Song J; Jin Y; Zhang C; Wu G
    Eur J Pharm Biopharm; 2020 Jul; 152():72-84. PubMed ID: 32376370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using a Membrane-Penetrating-Peptide to Anchor Ligands in the Liposome Membrane Facilitates Targeted Drug Delivery.
    Fan X; Xu H; Song J; Jin Y; Wink M; Wu G
    Bioconjug Chem; 2020 Jan; 31(1):113-122. PubMed ID: 31841319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy.
    Thomas E; Menon JU; Owen J; Skaripa-Koukelli I; Wallington S; Gray M; Mannaris C; Kersemans V; Allen D; Kinchesh P; Smart S; Carlisle R; Vallis KA
    Theranostics; 2019; 9(19):5595-5609. PubMed ID: 31534505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-Modified Erythrocyte Membrane-Cloaked Metal-Organic Framework Nanoparticles for Targeted Antitumor Therapy.
    Lin Y; Zhong Y; Chen Y; Li L; Chen G; Zhang J; Li P; Zhou C; Sun Y; Ma Y; Xie Z; Liao Q
    Mol Pharm; 2020 Sep; 17(9):3328-3341. PubMed ID: 32804508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
    Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
    Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ib-AMP4 insertion causes surface rearrangement in the phospholipid bilayer of biomembranes: Implications from quartz-crystal microbalance with dissipation.
    Fan X; Korytowski A; Makky A; Tanaka M; Wink M
    Biochim Biophys Acta Biomembr; 2018 Feb; 1860(2):617-623. PubMed ID: 29106975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
    Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
    Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A stabilized peptide ligand for multifunctional glioma targeted drug delivery.
    Ying M; Shen Q; Zhan C; Wei X; Gao J; Xie C; Yao B; Lu W
    J Control Release; 2016 Dec; 243():86-98. PubMed ID: 27693752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
    Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X
    Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein.
    Chen H; Sha H; Zhang L; Qian H; Chen F; Ding N; Ji L; Zhu A; Xu Q; Meng F; Yu L; Zhou Y; Liu B
    Int J Nanomedicine; 2018; 13():5347-5359. PubMed ID: 30254439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent.
    Accardo A; Salsano G; Morisco A; Aurilio M; Parisi A; Maione F; Cicala C; Tesauro D; Aloj L; De Rosa G; Morelli G
    Int J Nanomedicine; 2012; 7():2007-17. PubMed ID: 22619538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel tumor-targeted thermosensitive liposomal cerasome used for thermally controlled drug release.
    Li S; Yin G; Pu X; Huang Z; Liao X; Chen X
    Int J Pharm; 2019 Oct; 570():118660. PubMed ID: 31491484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
    Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
    Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use ofa Hydrophobic Binding Peptide Modified Lipid Nanocarrier Improving Tumor Distribution and Antitumor Efficacy.
    Gao W; Yang X; Lin Z; Gao S; He B; Mei B; Wang D; Yuan L; Zhang H; Dai W; Wang X; Wang J; Zhang X; Zhang Q
    J Biomed Nanotechnol; 2016 Jun; 12(6):1183-98. PubMed ID: 27319213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual targetable drug delivery system based on cell membrane camouflaged liposome for enhanced tumor targeting and improved anti-tumor efficiency.
    Duan M; Zhou D; Ke J; Chen Y; Wu W; Li Y; Ren J; Wang L; Zhang Z; Wang C
    Colloids Surf B Biointerfaces; 2024 Jun; 238():113892. PubMed ID: 38581834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-1 in Human Breast Cancer.
    Timur SS; Bhattarai P; Gürsoy RN; Vural İ; Khaw BA
    Pharm Res; 2017 Feb; 34(2):352-364. PubMed ID: 27896591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
    Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
    Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo.
    Bandekar A; Zhu C; Gomez A; Menzenski MZ; Sempkowski M; Sofou S
    Mol Pharm; 2013 Jan; 10(1):152-60. PubMed ID: 23134440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.